SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-000921
Filing Date
2021-01-12
Accepted
2021-01-12 07:15:13
Documents
12
Period of Report
2021-01-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K PAION LICENSE AGREEMENT ljpc-8k_20210112.htm   iXBRL 8-K 32051
  Complete submission text file 0001564590-21-000921.txt   161233

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ljpc-20210112.xsd EX-101.SCH 5828
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ljpc-20210112_lab.xml EX-101.LAB 19480
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ljpc-20210112_pre.xml EX-101.PRE 11671
5 EXTRACTED XBRL INSTANCE DOCUMENT ljpc-8k_20210112_htm.xml XML 3565
Mailing Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36282 | Film No.: 21522409
SIC: 2836 Biological Products, (No Diagnostic Substances)